Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
SAS Nanotechnologies Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner in 1 distinct art unit. The focus on Biotechnology & Pharmaceuticals indicates the specific domain of the company's current patent activity. With only 1 pending office action, the company's current engagement with the USPTO is limited in scope.
TRUONG, QUANGLONG N is the busiest examiner, holding 1 pending office action. As the only distinct examiner involved, TRUONG, QUANGLONG N is the sole arbiter of the 1 pending office action. This concentration within the art unit means that the prosecution strategy does not need to account for multiple examiner preferences. However, it also means the company's current success in the Biotechnology & Pharmaceuticals area is tied to the decisions of TRUONG, QUANGLONG N and the standards of the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18595120 | Encapsulation of Functional Additives in Partially-Open Microcapsules | TRUONG, QUANGLONG N | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18595120 | Encapsulation of Functional Additives in Partially-Open Microcapsules | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | — | Pending | Mar 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSAS Nanotechnologies Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quanglong N Truong has the most, with 1 of SAS Nanotechnologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
